Investment Analysts’ Weekly Ratings Changes for Axsome Therapeutics (AXSM)

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms:

• 2/24/2026 – Axsome Therapeutics had its price target raised by Royal Bank Of Canada from $219.00 to $222.00. They now have an “outperform” rating on the stock.
• 2/24/2026 – Axsome Therapeutics had its price target raised by UBS Group AG from $248.00 to $251.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Axsome Therapeutics was given a new $207.00 price target by Morgan Stanley.
• 2/24/2026 – Axsome Therapeutics had its price target raised by Guggenheim from $205.00 to $220.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Axsome Therapeutics had its price target raised by Wells Fargo & Company from $193.00 to $202.00. They now have an “overweight” rating on the stock.
• 2/23/2026 – Axsome Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $230.00 price target on the stock.
• 2/23/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 2/23/2026 – Axsome Therapeutics was given a new $200.00 price target by Truist Financial Corporation.
• 2/23/2026 – Axsome Therapeutics was given a new $215.00 price target by Jefferies Financial Group Inc..
• 2/23/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $225.00 price target on the stock.
• 2/19/2026 – Axsome Therapeutics was given a new $230.00 price target by Mizuho.
• 2/3/2026 – Axsome Therapeutics had its price target raised by Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 1/28/2026 – Axsome Therapeutics had its price target raised by Leerink Partners from $150.00 to $205.00. They now have an “outperform” rating on the stock.
• 1/21/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/21/2026 – Axsome Therapeutics had its price target raised by Royal Bank Of Canada from $212.00 to $219.00. They now have an “outperform” rating on the stock.
• 1/20/2026 – Axsome Therapeutics had its price target raised by HC Wainwright from $200.00 to $260.00. They now have a “buy” rating on the stock.
• 1/16/2026 – Axsome Therapeutics had its price target raised by Piper Sandler from $148.00 to $223.00. They now have an “overweight” rating on the stock.
• 1/14/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 1/13/2026 – Axsome Therapeutics was given a new $209.00 price target by Robert W. Baird.
• 1/13/2026 – Axsome Therapeutics had its price target raised by Wells Fargo & Company from $157.00 to $193.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Axsome Therapeutics was downgraded by Morgan Stanley from “overweight” to “reduce”.
• 1/8/2026 – Axsome Therapeutics had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $204.00 price target on the stock, up from $196.00.
• 1/6/2026 – Axsome Therapeutics had its price target raised by UBS Group AG from $163.00 to $248.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $225.00 price target on the stock.
• 1/5/2026 – Axsome Therapeutics had its price target raised by HC Wainwright from $185.00 to $200.00. They now have a “buy” rating on the stock.
• 1/2/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $205.00 price target on the stock.
• 12/31/2025 – Axsome Therapeutics was given a new $217.00 price target by Mizuho.
• 12/31/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $220.00 price target on the stock.
• 12/31/2025 – Axsome Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley.
• 12/31/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 12/31/2025 – Axsome Therapeutics had its price target raised by Needham & Company LLC from $154.00 to $169.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Herriot Tabuteau sold 78,703 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $171.28, for a total transaction of $13,480,249.84. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,238,183.12. This trade represents a 91.59% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 308,874 shares of company stock worth $51,390,805. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.